Over the past decade, the healthcare sector has encountered a range of significant challenges, leading it to lag well behind the broader US stock market. While the S&P 500 index has been on an impressive run over the last decade, averaging a return of 11.94%, the S&P 500 healthcare sector has managed to deliver less than half that amount, coming in at 5.79% over the decade. The recent underperformance this year can be attributed to large amounts of regulatory uncertainty. Nevertheless, this underperformance has meant healthcare looks much cheaper compared to the rest of the US market.
The current administration has introduced notable reforms in the Healthcare sector within a brief timeframe. Staffing reductions and the withdrawal of grant and contract funding have taken place within the Department of Health and Human Services (HHS). The reduction in staff has led to difficulties in the drug approval process, and reductions in spending have increased uncertainty regarding the future of drug development in the United States. Moreover, recent legislative actions, including decreased Medicaid and Affordable Care Act funding as specified in the Big Beautiful Bill, have decreased future earnings expectations for several large healthcare companies. In addition, Section 232 tariffs on imported pharmaceutical products have not yet been finalized and will also decrease the profits of these companies.
The recent period of underperformance may represent an attractive entry point. The significant valuation gap between healthcare and other market sectors offers a more favorable entry point for investors, while retaining the sector’s defensive qualities relative to the tech-heavy broader market. As regulatory uncertainty recedes, companies in this space are likely to benefit from improved sentiment, as current valuations reflect pessimistic scenarios that are unlikely. In addition, emerging technologies, including artificial intelligence and advanced robotics, are poised to enhance drug discovery and facilitate new medical procedures. The ageing population in the United States and other developed economies is expected to drive continued growth in healthcare expenditure. Given these defensive attributes and the comparatively attractive valuations, investing in healthcare makes sense at this time.
Valuation Gap between S&P 500 and S&P 500 Healthcare Sector (12m Forward P/E)
DISCLOSURES
The information provided is for educational purposes only. The views expressed here are those of the author and may not represent the views of Leo Wealth. Neither Leo Wealth nor the author makes any warranty or representation as to this information’s accuracy, completeness, or reliability. Please be advised that this content may contain errors, is subject to revision at all times, and should not be relied upon for any purpose. Under no circumstances shall Leo Wealth be liable to you or anyone else for damage stemming from the use or misuse of this information. Neither Leo Wealth nor the author offers legal or tax advice. Please consult the appropriate professional regarding your individual circumstance. Past performance is no guarantee of future results.
This material represents an assessment of the market and economic environment at a specific point in time. It is not intended to be a forecast of future events or a guarantee of future results.
Indices are unmanaged and investors cannot invest directly in an index. Unless otherwise noted, performance of indices does not account for any fees, commissions or other expenses that would be incurred. Returns do not include reinvested dividends.
The S&P 500 Index is a market capitalization–weighted index of 500 common stocks chosen for market size, liquidity, and industry group representation to represent US equity performance.
The S&P 500 Health Care Index comprises those companies included in the S&P 500 that are classified as members of the GICS® health care sector.
